



MEMBERSHIP

June 26, 2026

Company name: NIPRO CORPORATION
 Name of representative: Tsuyoshi Yamazaki, Representative Board Director President and CEO (Securities code: 8086; Prime Market)
 Inquiries: Mitsugu Sato, CSO
 Corporate Planning Headquarters
 (Telephone: +81-6-6310-6804)

Notice Concerning Changes in Subsidiary and Equity-Method Affiliate

NIPRO CORPORATION (the “Company”) hereby announces that, at the Board of Directors’ meeting held on June 26, 2026, it resolved to transfer its shares in Genuity, LLC (“Genuity”), a consolidated subsidiary, and Spryte Medical Holdings, LLC (“Spryte”), an equity-method affiliate, to its subsidiary NIPRO VASCULAR CORPORATION, as outlined below.

1. Reason for the Share Transfer

The Company is implementing organizational reforms aimed at operating its vascular business as an integrated end-to-end operation. As part of these reforms, the Company has decided to transfer its shares in Genuity and Spryte to NIPRO VASCULAR CORPORATION, which oversees the vascular business.

2. Overview of the Companies Subject to the Change

(1) Subsidiary to be Transferred

(1) Name	Genuity, LLC		
(2) Location	142 North Road, Suite G, Sudbury, MA, 01776 USA		
(3) Job title and name of representative	CEO David W. Kolstad		
(4) Description of business	Development and manufacturing of intravascular imaging medical devices		
(5) Share capital	143,445,859.70 U.S. dollars		
(6) Date of establishment	October 14, 2013		
(7) Major shareholders and ownership ratios	NIPRO CORPORATION 78%		
(8) Relationship between the Company and said company	Capital relationship	Hold 78% of the issued shares of the company.	
	Personnel relationship	None in particular	
	Business relationship	None in particular	
(9) Operating results and financial position for the last three years			
As of / Fiscal year ended	December 31, 2023	December 31, 2024	December 31, 2025
Net assets	△1,406	△6,537	△3,853
Total assets	4,143	3,111	6,474
Net assets per share (Yen)	△6 Yen	△78 Yen	△46 Yen

Net sales	438	871	523
Operating profit	△3,077	△4,560	△4,660
Ordinary profit	△3,214	△4,782	△5,010
Net profit	△3,214	△4,782	△4,616
Earnings per share (Yen)	△13 Yen	△57 Yen	△45 Yen
Dividend per share (Yen)	0 Yen	0 Yen	0 Yen

(Millions of yen, unless otherwise noted)

(2) Equity-Method Affiliate to be Transferred

(1) Name	Spryte Medical Holdings, LLC		
(2) Location	142 North Road, Suite G, Sudbury, MA, 01776 USA		
(3) Job title and name of representative	CEO David W. Kolstad		
(4) Description of business	Holding company		
(5) Share capital	85,000,000 U.S. dollars		
(6) Date of establishment	March 13, 2023		
(7) Major shareholders and ownership ratios	NIPRO CORPORATION 39%		
(8) Relationship between the Company and said company	Capital relationship	Hold 39% of the issued shares of the company.	
	Personnel relationship	None in particular	
	Business relationship	None in particular	
(9) Consolidated operating results and consolidated financial positions of said company for the last three years			
As of / Fiscal year ended	December 31, 2023	December 31, 2024	December 31, 2025
Consolidated net assets	2,127	△475	△270
Consolidated total assets	2,127	827	1,344
Consolidated net assets per share (Yen)	2,127 Yen	△6 Yen	△3 Yen
Consolidated net sales	0	0	0
Consolidated operating profit	△813	△2,112	△2,859
Consolidated ordinary profit	△754	△2,033	△2,810
Profit attributable to owners of parent	△754	△2,033	△2,810
Consolidated earnings per share (Yen)	△9 Yen	△24 Yen	△33 Yen
Dividend per share (Yen)	0 Yen	0 Yen	0 Yen

(Millions of yen, unless otherwise noted)

3. Overview of the Transferee

(1) Name	NIPRO VASCULAR CORPORATION
(2) Location	5F KDX Nagoya Sakae Building, 4-5-3, Sakae, Naka-ku, Nagoya, Aichi 460-0008
(3) Job title and name of representative	Tomohisa Handa, President and Representative Director

(4)	Description of business	Import, development, sale and manufacture of medical equipment and medical disposables	
(5)	Share capital	100 million yen	
(6)	Date of establishment	September 4, 1975	
(7)	Net assets	15,067,127,393 yen (as of March 31, 2026)	
(8)	Total assets	49,444,826,486 yen (as of March 31, 2026)	
(9)	Major shareholders and ownership ratios	NIPRO CORPORATION 100%	
(10)	Relationship between the Company and said company	Capital relationship	The Company owns 100% of the shares
		Personnel relationship	3 directors and 1 executive officer of the Company serve concurrently
		Business relationship	The Company has borrowed funds from the said company.

4. Number of Shares Transferred, Transfer Price and Ownership Before/After

(1) Genuity

(1)	Shares held before transfer	103,417,476 shares (Ratio of voting rights held: 78%)
(2)	Shares transferred	103,417,476 shares (Ratio of voting rights held: 78%)
(3)	Transfer price	21,347,784,351 Yen
(4)	Shares held after transfer	0 shares (Ratio of voting rights held: 0%)

(2) Spryte

(1)	Shares held before transfer	78,660,000 shares (Ratio of voting rights held: 39%)
(2)	Shares transferred	78,660,000 shares (Ratio of voting rights held: 61%)
(3)	Transfer price	4,989,574,800 Yen
(4)	Shares held after transfer	0 shares (Ratio of voting rights held: 0%)

5. Timetable

(1)	Date of resolution at the meeting of the Board of Directors	June 26, 2026
(2)	Date of commencement of share transfer	June 30, 2026 (scheduled)

6. Impact on Financial Results

This transaction is an intra-group restructuring, and it is not expected to have any impact on the Company's consolidated financial results.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.